Metastases Directed Therapy for Oligometastatic Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a phase III randomized study evaluating the benefit from adding metastases directed therapy and locoregional treatment of the primary in breast cancer patients diagnosed with de novo oligometastatic disease patients will be randomized to receive the standard of care (SOC) treatment vs. systemic treatment + Stereotactic Ablative Radiation Therapy. Responders will be randomized to either undergo loco-regional management of the primary tumor or not
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Kobiety w wieku od 18 do 70 lat.
- •Potwierdzony rak piersi.
- •Potwierdzony rozsiew raka do maksymalnie 5 miejsc poza mózgiem.
- •Ogólny stan zdrowia pozwalający na udział w badaniu (nieograniczający możliwości leczenia).
- •Brak przeciwwskazań do radioterapii.
✗ Disqualifies
- •Kobiety w ciąży i karmiące piersią.
- •Wcześniejsza radioterapia w tym samym miejscu mniej niż rok temu.
- •Aktywne choroby tkanki łącznej (np. reumatoidalne zapalenie stawów).
- •Szeroko rozprzestrzeniony rozsiew raka.
- •Przerzuty do mózgu.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 70 Years
- Last updated (source)
- November 22, 2023
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
National Cancer Institute
Cairo, Egypt
Trial contact
Rimoun R Boutrus, M.D.
Joseph S Nayrouz, M.D.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.